<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
    <title>Prostate Cancer Research</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/" />
    <link rel="self" type="application/atom+xml" href="http://thalasar.com/Prostate/atom.xml" />
   <id>tag:thalasar.com,2007:/Prostate//141</id>
    <link rel="service.post" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141" title="Prostate Cancer Research" />
    <updated>2007-08-09T03:14:57Z</updated>
    <subtitle>A blog devoted to surviving prostate cancer, finding treatment options, new drug therapies and new clinical trials. We cover the very latest research.</subtitle>
    <generator uri="http://www.sixapart.com/movabletype/">Movable Type 3.34</generator>
 
<entry>
    <title>Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/prostate_cancer_genetics/activation_of_pi3kakt_signalin.html" />
    <link rel="service.edit" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141/entry_id=36674" title="Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion." />
    <id>tag:thalasar.com,2007:/Prostate//141.36674</id>
    
    <published>2007-08-09T03:14:02Z</published>
    <updated>2007-08-09T03:14:57Z</updated>
    
    <summary></summary>
    <author>
        <name></name>
        
    </author>
            <category term="Prostate Cancer Genetics" />
    
    <content type="html" xml:lang="en" xml:base="http://thalasar.com/Prostate/">
        
        <![CDATA[<p>  	   		</p>

<p>Shukla, Sanjeev; Maclennan, Gregory T; Hartman, Douglas J; Fu, Pingfu; Resnick, Martin I; Gupta, Sanjay; ; 2007-06-07<br />
  	  	</p>

<p>Activated phosphoinositide 3-kinase (PI3K) and its downstream target Akt/PKB are important signaling ... PI3K-Akt signaling pathway in the invasion of prostate cancer cell lines and activation of this pathway in primary human prostate<br />
  		</p>

<p>International journal of cancer. Journal international du cancer<br />
  		</p>

<p>PubMed Database<br />
 <br />
 2 		Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. 	<br />
  		</p>

<p>Giovannucci, Edward; Liu, Yan; Platz, Elizabeth A; Stampfer, Meir J; Willett, Walter C; ; 2007-04-24<br />
  	  	</p>

<p>Risk factors for prostate cancer could differ for various sub-groups, such as for "aggressive" and "non-aggressive" cancers or by grade or stage. Determinants of mortality could differ from those for incidence.<br />
  		</p>

<p>International journal of cancer. Journal international du cancer<br />
  		</p>

<p>PubMed Database<br />
 <br />
 3 		Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation-A new paradigm for cooperation among prostate tumor cells. 	<br />
  		</p>

<p>Lapouge, Gaëlle; Erdmann, Eva; Marcias, Gemma; Jagla, Monika; Monge, Audrey; Kessler, Pascal; Serra, Sebastian; Lang, Hervé; Jacqmin, Didier; Bergerat, Jean-Pierre; Céraline, Jocelyn; ; 2007-05-31<br />
  	  	</p>

<p>The emergence of mutations in the androgen receptor (AR) gene is a recurrent event during progression of prostate cancer (PCa) on androgen ablation therapy. In this study, we show that nonsense mutations that lead to carboxyl-terminal end ...<br />
  		</p>

<p>International journal of cancer. Journal international du cancer<br />
  		</p>

<p>PubMed Database<br />
 <br />
 4 		Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo. 	<br />
  		</p>

<p>Gonzalez-Moreno, Oscar; Segura, Victor; Serrano, Diego; Nguewa, Paul; de Las Rivas, Javier; Calvo, Alfonso; ; 2007-05-24<br />
  	  	</p>

<p>New therapeutic agents are needed for the treatment of androgen-independent prostate cancer (PrCa). ... methylseleninic acid (MSA) on tumor stage-specific prostate cells derived from the C3 (1)/Tag model for PrCa: Pr111, a slow-growing ...<br />
  		</p>

<p>International journal of cancer. Journal international du cancer<br />
  		</p>

<p>PubMed Database<br />
 <br />
 5 		Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. 	<br />
  		</p>

<p>Travis, Ruth C; Key, Timothy J; Allen, Naomi E; Appleby, Paul N; Roddam, Andrew W; Rinaldi, Sabina; Egevad, Lars; Gann, Peter H; Rohrmann, Sabine; Linseisen, Jakob; Pischon, Tobias; Boeing, Heiner; Johnsen, Nina Føns; Tjønneland, Anne; Overvad, Kim; Kiem...; 2007-05-22<br />
  	  	</p>

<p>We examined the hypothesis that serum concentrations of circulating androgens and sex hormone binding globulin (SHBG) are associated with risk for prostate cancer in a case-control study nested ... European Prospective Investigation into Cancer ...<br />
  		</p>

<p>International journal of cancer. Journal international du cancer<br />
  		</p>

<p>PubMed Database<br />
 <br />
 6 		Fat and meat intake and prostate cancer risk: The multiethnic cohort study. 	<br />
  		</p>

<p>Park, Song-Yi; Murphy, Suzanne P; Wilkens, Lynne R; Henderson, Brian E; Kolonel, Laurence N; ; 2007-05-10<br />
  	  	</p>

<p>Dietary fat and meat as potential risk factors for prostate cancer have been the focus of many epidemiologic investigations, and findings from recent studies in particular have been inconsistent. ... association between these exposures and ...<br />
  		</p>

<p>International journal of cancer. Journal international du cancer<br />
  		</p>

<p>PubMed Database<br />
 <br />
 7 		Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D(3) derivative in prostate cancer cells. 	<br />
  		</p>

<p>Lambert, James R; Young, Christian D; Persons, Kelly S; Ray, Rahul; ; 2007-07-31<br />
  	  	</p>

<p>... has strong antiproliferative effects in cancer cells. But it is highly toxic at therapeutic doses. We have observed that 25-hydroxyvitamin D(3)-3-bromoacetate (25-OH-D(3)-3-BE), a derivative of 25-hydroxyvitamin ... prostate cancer cells.<br />
  		</p>

<p>Biochemical and biophysical research communications<br />
  		</p>

<p>PubMed Database<br />
 <br />
 8 		Intermittent chemotherapy in metastatic androgen-independent prostate cancer. 	<br />
  		</p>

<p>Bellmunt, Joaquim; Albiol, Santiago; Albanell, Joan; ; 2007-08-03<br />
  	  	</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 9 		Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective. 	<br />
  		</p>

<p>Hayes, Julia H; Barry, Michael J; Kantoff, Philip W; Stahl, James E; ; 2007-08-03<br />
  	  	</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 10 		An algorithm for managing the failure of external beam radiotherapy in prostate cancer. 	<br />
  		</p>

<p>Dudderidge, Tim; Payne, Heather; Emberton, Mark; ; 2007-06-19<br />
  	  	</p>

<p>OBJECTIVE To present a management algorithm for men with prostate cancer recurring after external beam radiotherapy (EBRT), based on a review of published reports, to assist clinicians in identifying<br />
  		</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 11 		Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer. 	<br />
  		</p>

<p>Sella, Avishay; Sternberg, Cora; Kovel, Svetlana; Yarom, Nirit; Skoneczna, Iwona; ; 2007-06-15<br />
  	  	</p>

<p>OBJECTIVE To assess the clinical pattern of progression and prostate-specific antigen doubling time (PSA-DT) after exposure ... cancer (AIPC). PATIENTS AND METHODS Fifty-five patients received docetaxel-based chemotherapy; data were collected ...<br />
  		</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 12 		The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme. 	<br />
  		</p>

<p>Roddam, Andrew W; Hamdy, Freddie C; Allen, Naomi E; Price, Christopher P; for the UK Prostate Cancer Risk Management Programme ; 2007-06-05<br />
  	  	</p>

<p>OBJECTIVE To assess the effects on the performance characteristics, in a prostate-cancer detection programme using prostate-specific antigen (PSA) levels, of a lower PSA threshold and the incorporation of reflex (free or complexed ...<br />
  		</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 13 		Bad expression influences time to androgen escape in prostate cancer. 	<br />
  		</p>

<p>Teo, Katy; Gemmell, Lisa; Mukherjee, Rono; Traynor, Pamela; Edwards, Joanne; ; 2007-06-05<br />
  	  	</p>

<p>OBJECTIVE To assess the role of selected downstream Bcl-2 family members (Bad, Bax, Bcl-2 and Bcl-xL) in the development of androgen-independent prostate cancer (AIPC), as androgen-deprivation ... is the treatment of choice in advanced prostate ...<br />
  		</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 14 		Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. 	<br />
  		</p>

<p>Shimizu, Yousuke; Segawa, Takehiko; Inoue, Takahiro; Shiraishi, Taizo; Yoshida, Toru; Toda, Yoshinobu; Yamada, Tomomi; Kinukawa, Naoko; Terada, Naoki; Kobayashi, Takashi; Kinoshita, Hidefumi; Kamoto, Toshiyuki; Nakamura, Eijiro; Ogawa, Osamu; ; 2007-06-05<br />
  	  	</p>

<p>OBJECTIVE To investigate the relationship between the expression of Akt (a serine/threonine kinase that plays a central role in tumorigenesis), phosphorylated Akt (p-Akt), prostate cancer tumour grade, androgen receptor (AR)-staining score, ...<br />
  		</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 15 		A more selective approach to prostate biopsy could be a safe and effective form of prostate cancer 'prevention'. 	<br />
  		</p>

<p>Parker, Chris; ; 2007-05-31<br />
  	  	</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 16 		Antiproliferation of human prostate cancer cells by ethanolic extracts of Brazilian propolis and its botanical origin. 	<br />
  		</p>

<p>Li, Hongzhen; Kapur, Aneesh; Yang, Jesse X; Srivastava, Shiv; McLeod, David G; Paredes-Guzman, Julio F; Daugsch, Andreas; Park, Yong K; Rhim, Johng S; ; 2007-08-03<br />
  	  	</p>

<p>Propolis is a resinous substance collected by bees (Apis mellifera) from ... dracunculifolia), and propolis group 3 on proliferation of metastasis (DU145 and PC-3) and primary malignant tumor (RC58T/h/SA#4)-derived human prostate cancer cells.<br />
  		</p>

<p>International journal of oncology<br />
  		</p>

<p>PubMed Database<br />
 <br />
 17 		Glyceraldehyde-3-phosphate Dehydrogenase Enhances Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells. 	<br />
  		</p>

<p>Harada, Naoki; Yasunaga, Ryoko; Higashimura, Yasuki; Yamaji, Ryoichi; Fujimoto, Katsumi; Moss, Joel; Inui, Hiroshi; Nakano, Yoshihisa; ; 2007-06-08<br />
  	  	</p>

<p>Androgen receptor (AR) functions as a transcriptional factor for genes involved in proliferation and differentiation of normal and cancerous prostate cells. Coactivators that bind to AR are required for maximal androgen action.<br />
  		</p>

<p>The Journal of biological chemistry<br />
  		</p>

<p>PubMed Database<br />
 <br />
 18 		HPLC for stress-free screening of potential prostate cancer marker catechol estrogens in urine using a diamond-electrode electrochemical and a fluorescence detector. 	<br />
  		</p>

<p>Katayama, Masatoki Takamatsu, Kiyoshi Kaneko, Satoru Miyaji, Keisuke Ishikawa, Hiromichi Matsuda, Yoshifumi ; 2007-08-03<br />
  	  	</p>

<p>Improvement of the sensitivity and specificity of a simultaneous stress-free screening method for catechol estrogens as a potential prostate cancer marker ... the sensitivity and specificity of the prostatic<br />
  		</p>

<p>PubMed Database<br />
 <br />
 19 		Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. 	<br />
  		</p>

<p>Tomlins, Scott A; Laxman, Bharathi; Dhanasekaran, Saravana M; Helgeson, Beth E; Cao, Xuhong; Morris, David S; Menon, Anjana; Jing, Xiaojun; Cao, Qi; Han, Bo; Yu, Jindan; Wang, Lei; Montie, James E; Rubin, Mark A; Pienta, Kenneth J; Roulston, Diane; Shah,...; 2007-08-03<br />
  	  	</p>

<p>Recently, we identified recurrent gene fusions involving the 5' untranslated region of the androgen-regulated gene TMPRSS2 and the ETS (E26 transformation-specific) family genes ERG, ETV1 or ETV4 in most prostate cancers.<br />
  		</p>

<p>Nature<br />
  		</p>

<p>PubMed Database<br />
 <br />
 20 		cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. 	<br />
  		</p>

<p>Wu, D; Zhau, H E; Huang, W-C; Iqbal, S; Habib, F K; Sartor, O; Cvitanovic, L; Marshall, F F; Xu, Z; Chung, L W K; ; 2007-02-22<br />
  	  	</p>

<p>Aberrant expression of vascular endothelial growth factor (VEGF) is associated with human prostate cancer (PCa) metastasis and poor clinical outcome. We found that both phosphorylation of cyclic AMP-responsive element-binding protein (CREB) ...<br />
  		</p>

<p>Oncogene<br />
  		</p>

<p>PubMed Database<br />
 <br />
 21 		A Refined Comorbidity Measurement Algorithm for Claims-Based Studies of Breast, Prostate, Colorectal, and Lung Cancer Patients. 	<br />
  		</p>

<p>Klabunde, Carrie N Legler, Julie M Warren, Joan L Baldwin, Laura-Mae Schrag, Deborah ; 2007-05-29<br />
  	  	</p>

<p>PURPOSE: We evaluated (i) how combining comorbid conditions identified from Medicare inpatient or physician ... linked database, from which four cohorts of cancer patients were derived: breast (n = 26,377), prostate (n = 53,503), colorectal (n<br />
  		</p>

<p>PubMed Database<br />
 <br />
 22 		Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells. 	<br />
  		</p>

<p>Lee, Dong I; Sumbilla, Carlota; Lee, Myounghee; Natesavelalar, Chidambaram; Klein, Michael G; Ross, Douglas D; Inesi, Giuseppe; Hussain, Arif; ; 2007-05-04<br />
  	  	</p>

<p>Cells with increasing resistance to the sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPase (SERCA) inhibitor thapsigargin (TG), ranging from 60-fold (PC3/TG(10) cells) ... Thus, novel TG-specific resistance mechanisms are recruited by these cancer cells.<br />
  		</p>

<p>Archives of biochemistry and biophysics<br />
  		</p>

<p>PubMed Database<br />
 <br />
 23 		Targeting Human {gamma}{delta} T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer. 	<br />
  		</p>

<p>Dieli, Francesco; Vermijlen, David; Fulfaro, Fabio; Caccamo, Nadia; Meraviglia, Serena; Cicero, Giuseppe; Roberts, Andrew; Buccheri, Simona; D'Asaro, Matilde; Gebbia, Nicola; Salerno, Alfredo; Eberl, Matthias; Hayday, Adrian C; ; 2007-08-03<br />
  	  	</p>

<p>The increasing evidence that gammadelta T cells have potent antitumor activity suggests ... trial in metastatic hormone-refractory prostate cancer to examine the feasibility and consequences of using the gammadelta T-cell agonist zoledronate,<br />
  		</p>

<p>Cancer research<br />
  		</p>

<p>PubMed Database<br />
 <br />
 24 		Guggulsterone-Induced Apoptosis in Human Prostate Cancer Cells Is Caused by Reactive Oxygen Intermediate Dependent Activation of c-Jun NH2-Terminal Kinase. 	<br />
  		</p>

<p>Singh, Shivendra V; Choi, Sunga; Zeng, Yan; Hahm, Eun-Ryeong; Xiao, Dong; ; 2007-08-03<br />
  	  	</p>

<p>Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, causes apoptosis in cancer cells but ... We now show that guggulsterone-induced cell death in human prostate cancer cells is caused by reactive oxygen intermediate (ROI)-dependent activation of c-Jun NH(2)-terminal kinase (JNK).<br />
  		</p>

<p>Cancer research<br />
  		</p>

<p>PubMed Database<br />
 <br />
 25 		Tendon abnormalities mimicking metastatic disease in patients with prostate cancer. 	<br />
  		</p>

<p>Kerimoglu, Ulku; Kaya, Diana; Ergen, Fatma Bilge; ; 2007-08-02<br />
  	  	</p>

<p>We present plain x-ray examination, bone scintigraphy, computed tomography, and magnetic resonance imaging of 2 patients diagnosed with prostate cancer who complained of hip pain. Bone scintigraphy was suggestive for metastases.<br />
  		</p>

<p>Clinical nuclear medicine<br />
  		</p>

<p>PubMed Database<br />
 <br />
 26 		Blood biomarkers for prostate cancer detection and prognosis. 	<br />
  		</p>

<p>Shariat, Shahrokh F Karam, Jose A Roehrborn, Claus G ; 2007-07-31<br />
  	  	</p>

<p>Prostate cancer is the most noncutaneous malignancy diagnosed in men in the USA. The discovery of prostate-specific antigen (PSA) revolutionized prostate cancer diagnosis and management in the 1990s.<br />
  		</p>

<p>PubMed Database<br />
 <br />
 27 		Prostate-specific antigen kinetics after failure of primary prostate cancer therapy: a valuable prognostic factor. 	<br />
  		</p>

<p>Pickles, Tom; ; 2007-07-31<br />
  	  	</p>

<p>Evaluation of: Freedland SJ, Humphreys EB, Mangold LA et al.: Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause ...<br />
  		</p>

<p>Future oncology (London, England)<br />
  		</p>

<p>PubMed Database<br />
 <br />
 28 		Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure. 	<br />
  		</p>

<p>Jackson, Crystal L; Dreaden, Tina M; Theobald, Lisa K; Tran, Nhien M; Beal, Tiffany L; Eid, Manal; Gao, Mu Yun; Shirley, Robert B; Stoffel, Mark T; Kumar, M Vijay; Mohnen, Debra; ; 2007-05-22<br />
  	  	</p>

<p>Treatment options for androgen-independent prostate cancer cells are limited. Therefore, it is critical to identify agents that induce death of both androgen-responsive and androgen-insensitive cells.<br />
  		</p>

<p>Glycobiology<br />
  		</p>

<p>PubMed Database<br />
 <br />
 29 		Stem cells in prostate cancer initiation and progression. 	<br />
  		</p>

<p>Lawson, Devon A; Witte, Owen N; ; 2007-08-03<br />
  	  	</p>

<p>... paradigm shift in our understanding of cancer as a disease of stem cells. This Review focuses on the application of these concepts to investigation of the role of stem cells in prostate cancer initiation and progression.<br />
  		</p>

<p>The Journal of clinical investigation<br />
  		</p>

<p>PubMed Database<br />
 <br />
 30 		Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients. 	<br />
  		</p>

<p>Cai, Tommaso; Bartoletti, Riccardo; ; 2007-08-01<br />
  	  	</p>

<p>Journal of clinical oncology : official journal of the American Society of Clinical Oncology<br />
  		</p>

<p>PubMed Database<br />
 <br />
 31 		Subcutaneous midazolam as a cause of extrapyramidal side effects in a patient with prostate cancer. 	<br />
  		</p>

<p>Brown, Duncan J F; McArthur, Dorothy; Moulsdale, Helen; ; 2007-07-03<br />
  	  	</p>

<p>Journal of pain and symptom management<br />
  		</p>

<p>PubMed Database<br />
 <br />
 32 		Prostate cancer screening an individual decision. 	<br />
  		</p>

<p>Holcomb, Susan Simmons; ; 2007-08-02<br />
  	  	</p>

<p>The Nurse practitioner<br />
  		</p>

<p>PubMed Database<br />
 <br />
 33 		[Imaging procedures to diagnose prostate cancer.] 	<br />
  		</p>

<p>Seitz, M Scher, B Scherr, M Tilki, D Schlenker, B Gratzke, C Schipf, A Stanislaus, P Müller-Lisse, U Reich, O Stief, C ; 2007-08-01<br />
  	  	</p>

<p>Prostate cancer is one of the most frequent malignant diseases in men. ... progress achieved in imaging procedures, prostate biopsy is the gold standard for diagnosing prostate cancer.<br />
  		</p>

<p>PubMed Database<br />
 <br />
 34 		Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. 	<br />
  		</p>

<p>Tam, L; McGlynn, L M; Traynor, P; Mukherjee, R; Bartlett, J M S; Edwards, J; ; 2007-06-28<br />
  	  	</p>

<p>The main cause of prostate cancer-related mortality is the development of hormone-refractory disease. ... IL-6 are raised in hormone-refractory prostate cancer patients and evidence from cell line studies suggests that the ...<br />
  		</p>

<p>British journal of cancer<br />
  		</p>

<p>PubMed Database<br />
 <br />
 35 		Association between FAS polymorphism and prostate cancer development. 	<br />
  		</p>

<p>Lima, L Morais, A Lobo, F Calais-da-Silva, F M Calais-da-Silva, F E Medeiros, R ; 2007-08-02<br />
  	  	</p>

<p>The role of FAS polymorphisms in prostate cancer has not been studied. ... -670 genotypes in DNA from 904 men: 657 prostate ... inhibition caused by the soluble form.Prostate Cancer and Prostatic Diseases<br />
  		</p>

<p>PubMed Database<br />
 <br />
 36 		Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. 	<br />
  		</p>

<p>Halabi, Susan Ou, San-San Vogelzang, Nicholas J Small, Eric J ; 2007-08-01<br />
  	  	</p>

<p>BACKGROUND.: Obesity has a variety of adverse health outcomes, but to the authors' knowledge, the effect of obesity on outcome in patients with advanced prostate cancer is not known. ... with metastatic, castration-recurrent prostate ...<br />
  		</p>

<p>PubMed Database<br />
 <br />
 37 		A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. 	<br />
  		</p>

<p>Gross, Mitchell Higano, Celestia Pantuck, Allan Castellanos, Olga Green, Erica Nguyen, Koo Agus, David B ; 2007-07-31<br />
  	  	</p>

<p>ABSTRACT: BACKGROUND: Docetaxel is the standard first-line agent for the treatment of androgen-independent prostate cancer (AIPC). ... toxicity of cytotoxic chemotherapy for prostate cancer.<br />
  		</p>

<p>PubMed Database<br />
 <br />
 38 		Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. 	<br />
  		</p>

<p>Saigal, Christopher S Gore, John L Krupski, Tracey L Hanley, Janet Schonlau, Matthias Litwin, Mark S And the Urologic Diseases in America Project ; 2007-07-28<br />
  	  	</p>

<p>BACKGROUND.: The use of androgen deprivation therapy (ADT) in the treatment of men with prostate cancer has risen sharply. ... common reason for death among men with prostate cancer who do not die of the disease itself, data ...<br />
  		</p>

<p>PubMed Database<br />
 <br />
 39 		The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy. 	<br />
  		</p>

<p>Vickers, Andrew J Ulmert, David Serio, Angel M Björk, Thomas Scardino, Peter T Eastham, James A Berglund, Göran Lilja, Hans ; 2007-07-28<br />
  	  	</p>

<p>Both benign and malignant prostate diseases elevate total prostate-specific antigen (tPSA), and the incidence of ... fPSA, tPSA and hK2 were measured in archived plasma collected during 1974-1986 in 501 men subsequently diagnosed with prostate cancer up to 1999 and in 1,292 matched controls.<br />
  		</p>

<p>PubMed Database<br />
 <br />
 40 		The androgen receptor and prostate cancer: A role for sexual selection and sexual conflict? 	<br />
  		</p>

<p>Summers, Kyle Crespi, Bernard ; 2007-07-28<br />
  	  	</p>

<p>We propose and evaluate the hypothesis that the CAG repeat region of the androgen receptor represents a locus ... However, short repeats are also associated with increased risk of prostate cancer, and with more aggressive forms of the disease.<br />
  		</p>

<p>PubMed Database<br />
 <br />
 41 		IS OBESITY A RISK FACTOR FOR PROSTATE CANCER? 	<br />
  		</p>

<p>Goldstraw, Miles A Besrani, Dler Amoroso, Peter Kirby, Roger S ; 2007-07-31<br />
  	  	</p>

<p>PubMed Database<br />
 <br />
 42 		Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. 	<br />
  		</p>

<p>Ismail, Mohamed Ahmed, Shwan Kastner, Christof Davies, John ; 2007-07-31<br />
  	  	</p>

<p>OBJECTIVE To report the short- to intermediate-term experience of using salvage targeted cryoablation of the prostate (TCAP) for the recurrence of localized prostate cancer after radiotherapy.<br />
  		</p>

<p>PubMed Database<br />
 <br />
 43 		The role of intermittent androgen deprivation in prostate cancer. 	<br />
  		</p>

<p>Boccon-Gibod, Laurent Hammerer, Peter Madersbacher, Stephan Mottet, Nicolas Prayer-Galetti, Tommaso Tunn, Ulf ; 2007-07-31<br />
  	  	</p>

<p>PubMed Database<br />
 <br />
 44 		Targeting uPA/uPAR in prostate cancer. 	<br />
  		</p>

<p>Li, Y Cozzi, P J ; 2007-07-31<br />
  	  	</p>

<p>Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite significant advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to secondary disease ...<br />
  		</p>

<p>PubMed Database<br />
 <br />
 45 		PSA Nadir Is a Significant Predictor of Treatment Failure after High-Intensity Focussed Ultrasound (HIFU) Treatment of Localised Prostate Cancer. 	<br />
  		</p>

<p>Ganzer, Roman Rogenhofer, Sebastian Walter, Bernhard Lunz, Jens-Claudio Schostak, Martin Wieland, Wolf F Blana, Andreas ; 2007-07-31<br />
  	  	</p>

<p>OBJECTIVES: To assess if prostate-specific antigen (PSA) nadir is an independent predictor of treatment failure and disease-free ... (Ablatherm((R)), EDAP, Lyon, France) for localised prostate cancer without previous hormonal therapy were evaluated retrospectively.<br />
  		</p>

<p>PubMed Database<br />
 <br />
 46 		Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. 	<br />
  		</p>

<p>Doak, Shareen H; Jenkins, Spencer A; Hurle, Rhidian A; Varma, Murali; Hawizy, Azad; Kynaston, Howard G; Parry, James M; ; 2007-07-28<br />
  	  	</p>

<p>Abnormal expression of bone morphogenic proteins (BMP) has been reported in prostate cancer as compared to benign prostatic tissue. ... this possibility in patients with early prostate cancer.<br />
  		</p>

<p>Cancer genetics and cytogenetics<br />
  		</p>

<p>PubMed Database<br />
 <br />
 47 		Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. 	<br />
  		</p>

<p>Gudmundsson, Julius; Sulem, Patrick; Steinthorsdottir, Valgerdur; Bergthorsson, Jon T; Thorleifsson, Gudmar; Manolescu, Andrei; Rafnar, Thorunn; Gudbjartsson, Daniel; Agnarsson, Bjarni A; Baker, Adam; Sigurdsson, Asgeir; Benediktsdottir, Kristrun R; Jako...; 2007-07-03<br />
  	  	</p>

<p>We performed a genome-wide association scan to search for sequence variants conferring risk of prostate cancer using 1,501 Icelandic men with prostate cancer and 11,290 controls. Follow-up studies involving three additional ...<br />
  		</p>

<p>Nature genetics<br />
  		</p>

<p>PubMed Database<br />
 <br />
 48 		Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. 	<br />
  		</p>

<p>Pickles, Tom Ruether, J Dean Weir, Lorna Carlson, Linda Jakulj, Fabijana the SCRN Communication Team† ; 2007-05-30<br />
  	  	</p>

<p>OBJECTIVES To review the psychosocial needs of men undergoing active surveillance (AS, the monitoring of early prostate cancer, with curative intervention only if the disease significantly progresses) for prostate cancer, ...<br />
  		</p>

<p>PubMed Database<br />
 <br />
 49 		Does active surveillance for men with localized prostate cancer carry psychological morbidity? 	<br />
  		</p>

<p>Burnet, Katriina L; Parker, Chris; Dearnaley, David; Brewin, Chris R; Watson, Maggie; ; 2007-06-07<br />
  	  	</p>

<p>OBJECTIVES To investigate, in a cross-sectional study, the prevalence of anxiety and depression in patients with localised prostate cancer managed by active surveillance, compared with those receiving immediate treatment, as active surveillance ...<br />
  		</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 50 		Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. 	<br />
  		</p>

<p>Briganti, Alberto; Shariat, Shahrokh F; Chun, Felix K-H; Hutterer, Georg C; Roehrborn, Claus G; Gallina, Andrea; Rigatti, Patrizio; Valiquette, Luc; Montorsi, Francesco; Karakiewicz, Pierre I; ; 2007-06-19<br />
  	  	</p>

<p>OBJECTIVE To test whether the rate of lymph node invasion (LNI) differs ... PATIENTS AND METHODS In all, 1385 men had RP with bilateral lymphadenectomy for clinically localized prostate cancer (587 from Dallas, Texas and 798 from Milan, Italy).<br />
  		</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 51 		Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. 	<br />
  		</p>

<p>Curigliano, Giuseppe; De Braud, Filippo; Teresa Sandri, Maria; Renne, Giuseppe; Zorzino, Laura; Scardino, Epifanio; Rocco, Bernardo; Spitaleri, Gianluca; De Pas, Tommaso; Noberasco, Cristina; Nolè, Franco; Verweij, Fabrizio; Matei, Victor; De Cobelli, Ot...; 2007-08-02<br />
  	  	</p>

<p>We investigated efficacy of gefitinib in hormone-refractory prostate cancer. ... 2004, 23 patients with hormone-refractory prostate cancer were assigned to receive 250 mg oral gefitinib daily in addition to antiandrogen and ...<br />
  		</p>

<p>Anti-cancer drugs<br />
  		</p>

<p>PubMed Database<br />
 <br />
 52 		Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling. 	<br />
  		</p>

<p>Yang, Yang; Ikezoe, Takayuki; Zheng, Zhixing; Taguchi, Hirokuni; Koeffler, H Phillip; Zhu, Wei-Guo; ; 2007-08-03<br />
  	  	</p>

<p>PC-SPES is an eight-herb mixture that has an activity against prostate cancer. ... Saw Palmetto induced growth arrest of prostate cancer LNCaP, DU145, and PC3 cells with ED50s of approximately<br />
  		</p>

<p>International journal of oncology<br />
  		</p>

<p>PubMed Database<br />
 <br />
 53 		Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. 	<br />
  		</p>

<p>Lecouvet, Frédéric E; Geukens, Daphné; Stainier, Annabelle; Jamar, François; Jamart, Jacques; d'Othée, Bertrand Janne; Therasse, Patrick; Berg, Bruno Vande; Tombal, Bertrand; ; 2007-08-01<br />
  	  	</p>

<p>PURPOSE To evaluate the diagnostic performance, costs, and impact on therapy of one-step magnetic resonance imaging (MRI) of the axial skeleton (MRIas) for detecting bone metastases in patients with high-risk prostate cancer<br />
  		</p>

<p>Journal of clinical oncology : official journal of the American Society of Clinical Oncology<br />
  		</p>

<p>PubMed Database<br />
 <br />
 <br />
 Documents from PubMed Database 53 Results Retrieved<br />
 <br />
 1 		Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. 	<br />
  		</p>

<p>Shukla, Sanjeev; Maclennan, Gregory T; Hartman, Douglas J; Fu, Pingfu; Resnick, Martin I; Gupta, Sanjay; ; 2007-06-07<br />
  	  	</p>

<p>Activated phosphoinositide 3-kinase (PI3K) and its downstream target Akt/PKB are important signaling ... PI3K-Akt signaling pathway in the invasion of prostate cancer cell lines and activation of this pathway in primary human prostate<br />
  		</p>

<p>International journal of cancer. Journal international du cancer<br />
  		</p>

<p>PubMed Database<br />
 <br />
 2 		Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. 	<br />
  		</p>

<p>Giovannucci, Edward; Liu, Yan; Platz, Elizabeth A; Stampfer, Meir J; Willett, Walter C; ; 2007-04-24<br />
  	  	</p>

<p>Risk factors for prostate cancer could differ for various sub-groups, such as for "aggressive" and "non-aggressive" cancers or by grade or stage. Determinants of mortality could differ from those for incidence.<br />
  		</p>

<p>International journal of cancer. Journal international du cancer<br />
  		</p>

<p>PubMed Database<br />
 <br />
 3 		Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation-A new paradigm for cooperation among prostate tumor cells. 	<br />
  		</p>

<p>Lapouge, Gaëlle; Erdmann, Eva; Marcias, Gemma; Jagla, Monika; Monge, Audrey; Kessler, Pascal; Serra, Sebastian; Lang, Hervé; Jacqmin, Didier; Bergerat, Jean-Pierre; Céraline, Jocelyn; ; 2007-05-31<br />
  	  	</p>

<p>The emergence of mutations in the androgen receptor (AR) gene is a recurrent event during progression of prostate cancer (PCa) on androgen ablation therapy. In this study, we show that nonsense mutations that lead to carboxyl-terminal end ...<br />
  		</p>

<p>International journal of cancer. Journal international du cancer<br />
  		</p>

<p>PubMed Database<br />
 <br />
 4 		Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo. 	<br />
  		</p>

<p>Gonzalez-Moreno, Oscar; Segura, Victor; Serrano, Diego; Nguewa, Paul; de Las Rivas, Javier; Calvo, Alfonso; ; 2007-05-24<br />
  	  	</p>

<p>New therapeutic agents are needed for the treatment of androgen-independent prostate cancer (PrCa). ... methylseleninic acid (MSA) on tumor stage-specific prostate cells derived from the C3 (1)/Tag model for PrCa: Pr111, a slow-growing ...<br />
  		</p>

<p>International journal of cancer. Journal international du cancer<br />
  		</p>

<p>PubMed Database<br />
 <br />
 5 		Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. 	<br />
  		</p>

<p>Travis, Ruth C; Key, Timothy J; Allen, Naomi E; Appleby, Paul N; Roddam, Andrew W; Rinaldi, Sabina; Egevad, Lars; Gann, Peter H; Rohrmann, Sabine; Linseisen, Jakob; Pischon, Tobias; Boeing, Heiner; Johnsen, Nina Føns; Tjønneland, Anne; Overvad, Kim; Kiem...; 2007-05-22<br />
  	  	</p>

<p>We examined the hypothesis that serum concentrations of circulating androgens and sex hormone binding globulin (SHBG) are associated with risk for prostate cancer in a case-control study nested ... European Prospective Investigation into Cancer ...<br />
  		</p>

<p>International journal of cancer. Journal international du cancer<br />
  		</p>

<p>PubMed Database<br />
 <br />
 6 		Fat and meat intake and prostate cancer risk: The multiethnic cohort study. 	<br />
  		</p>

<p>Park, Song-Yi; Murphy, Suzanne P; Wilkens, Lynne R; Henderson, Brian E; Kolonel, Laurence N; ; 2007-05-10<br />
  	  	</p>

<p>Dietary fat and meat as potential risk factors for prostate cancer have been the focus of many epidemiologic investigations, and findings from recent studies in particular have been inconsistent. ... association between these exposures and ...<br />
  		</p>

<p>International journal of cancer. Journal international du cancer<br />
  		</p>

<p>PubMed Database<br />
 <br />
 7 		Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D(3) derivative in prostate cancer cells. 	<br />
  		</p>

<p>Lambert, James R; Young, Christian D; Persons, Kelly S; Ray, Rahul; ; 2007-07-31<br />
  	  	</p>

<p>... has strong antiproliferative effects in cancer cells. But it is highly toxic at therapeutic doses. We have observed that 25-hydroxyvitamin D(3)-3-bromoacetate (25-OH-D(3)-3-BE), a derivative of 25-hydroxyvitamin ... prostate cancer cells.<br />
  		</p>

<p>Biochemical and biophysical research communications<br />
  		</p>

<p>PubMed Database<br />
 <br />
 8 		Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. 	<br />
  		</p>

<p>Curigliano, Giuseppe; De Braud, Filippo; Teresa Sandri, Maria; Renne, Giuseppe; Zorzino, Laura; Scardino, Epifanio; Rocco, Bernardo; Spitaleri, Gianluca; De Pas, Tommaso; Noberasco, Cristina; Nolè, Franco; Verweij, Fabrizio; Matei, Victor; De Cobelli, Ot...; 2007-08-02<br />
  	  	</p>

<p>We investigated efficacy of gefitinib in hormone-refractory prostate cancer. ... 2004, 23 patients with hormone-refractory prostate cancer were assigned to receive 250 mg oral gefitinib daily in addition to antiandrogen and ...<br />
  		</p>

<p>Anti-cancer drugs<br />
  		</p>

<p>PubMed Database<br />
 <br />
 9 		Intermittent chemotherapy in metastatic androgen-independent prostate cancer. 	<br />
  		</p>

<p>Bellmunt, Joaquim; Albiol, Santiago; Albanell, Joan; ; 2007-08-03<br />
  	  	</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 10 		Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective. 	<br />
  		</p>

<p>Hayes, Julia H; Barry, Michael J; Kantoff, Philip W; Stahl, James E; ; 2007-08-03<br />
  	  	</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 11 		An algorithm for managing the failure of external beam radiotherapy in prostate cancer. 	<br />
  		</p>

<p>Dudderidge, Tim; Payne, Heather; Emberton, Mark; ; 2007-06-19<br />
  	  	</p>

<p>OBJECTIVE To present a management algorithm for men with prostate cancer recurring after external beam radiotherapy (EBRT), based on a review of published reports, to assist clinicians in identifying<br />
  		</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 12 		Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. 	<br />
  		</p>

<p>Briganti, Alberto; Shariat, Shahrokh F; Chun, Felix K-H; Hutterer, Georg C; Roehrborn, Claus G; Gallina, Andrea; Rigatti, Patrizio; Valiquette, Luc; Montorsi, Francesco; Karakiewicz, Pierre I; ; 2007-06-19<br />
  	  	</p>

<p>OBJECTIVE To test whether the rate of lymph node invasion (LNI) differs ... PATIENTS AND METHODS In all, 1385 men had RP with bilateral lymphadenectomy for clinically localized prostate cancer (587 from Dallas, Texas and 798 from Milan, Italy).<br />
  		</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 13 		Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer. 	<br />
  		</p>

<p>Sella, Avishay; Sternberg, Cora; Kovel, Svetlana; Yarom, Nirit; Skoneczna, Iwona; ; 2007-06-15<br />
  	  	</p>

<p>OBJECTIVE To assess the clinical pattern of progression and prostate-specific antigen doubling time (PSA-DT) after exposure ... cancer (AIPC). PATIENTS AND METHODS Fifty-five patients received docetaxel-based chemotherapy; data were collected ...<br />
  		</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 14 		Does active surveillance for men with localized prostate cancer carry psychological morbidity? 	<br />
  		</p>

<p>Burnet, Katriina L; Parker, Chris; Dearnaley, David; Brewin, Chris R; Watson, Maggie; ; 2007-06-07<br />
  	  	</p>

<p>OBJECTIVES To investigate, in a cross-sectional study, the prevalence of anxiety and depression in patients with localised prostate cancer managed by active surveillance, compared with those receiving immediate treatment, as active surveillance ...<br />
  		</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 15 		The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme. 	<br />
  		</p>

<p>Roddam, Andrew W; Hamdy, Freddie C; Allen, Naomi E; Price, Christopher P; for the UK Prostate Cancer Risk Management Programme ; 2007-06-05<br />
  	  	</p>

<p>OBJECTIVE To assess the effects on the performance characteristics, in a prostate-cancer detection programme using prostate-specific antigen (PSA) levels, of a lower PSA threshold and the incorporation of reflex (free or complexed ...<br />
  		</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 16 		Bad expression influences time to androgen escape in prostate cancer. 	<br />
  		</p>

<p>Teo, Katy; Gemmell, Lisa; Mukherjee, Rono; Traynor, Pamela; Edwards, Joanne; ; 2007-06-05<br />
  	  	</p>

<p>OBJECTIVE To assess the role of selected downstream Bcl-2 family members (Bad, Bax, Bcl-2 and Bcl-xL) in the development of androgen-independent prostate cancer (AIPC), as androgen-deprivation ... is the treatment of choice in advanced prostate ...<br />
  		</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 17 		Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. 	<br />
  		</p>

<p>Shimizu, Yousuke; Segawa, Takehiko; Inoue, Takahiro; Shiraishi, Taizo; Yoshida, Toru; Toda, Yoshinobu; Yamada, Tomomi; Kinukawa, Naoko; Terada, Naoki; Kobayashi, Takashi; Kinoshita, Hidefumi; Kamoto, Toshiyuki; Nakamura, Eijiro; Ogawa, Osamu; ; 2007-06-05<br />
  	  	</p>

<p>OBJECTIVE To investigate the relationship between the expression of Akt (a serine/threonine kinase that plays a central role in tumorigenesis), phosphorylated Akt (p-Akt), prostate cancer tumour grade, androgen receptor (AR)-staining score, ...<br />
  		</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 18 		A more selective approach to prostate biopsy could be a safe and effective form of prostate cancer 'prevention'. 	<br />
  		</p>

<p>Parker, Chris; ; 2007-05-31<br />
  	  	</p>

<p>BJU international<br />
  		</p>

<p>PubMed Database<br />
 <br />
 19 		Antiproliferation of human prostate cancer cells by ethanolic extracts of Brazilian propolis and its botanical origin. 	<br />
  		</p>

<p>Li, Hongzhen; Kapur, Aneesh; Yang, Jesse X; Srivastava, Shiv; McLeod, David G; Paredes-Guzman, Julio F; Daugsch, Andreas; Park, Yong K; Rhim, Johng S; ; 2007-08-03<br />
  	  	</p>

<p>Propolis is a resinous substance collected by bees (Apis mellifera) from ... dracunculifolia), and propolis group 3 on proliferation of metastasis (DU145 and PC-3) and primary malignant tumor (RC58T/h/SA#4)-derived human prostate cancer cells.<br />
  		</p>

<p>International journal of oncology<br />
  		</p>

<p>PubMed Database<br />
 <br />
 20 		Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling. 	<br />
  		</p>

<p>Yang, Yang; Ikezoe, Takayuki; Zheng, Zhixing; Taguchi, Hirokuni; Koeffler, H Phillip; Zhu, Wei-Guo; ; 2007-08-03<br />
  	  	</p>

<p>PC-SPES is an eight-herb mixture that has an activity against prostate cancer. ... Saw Palmetto induced growth arrest of prostate cancer LNCaP, DU145, and PC3 cells with ED50s of approximately<br />
  		</p>

<p>International journal of oncology<br />
  		</p>

<p>PubMed Database<br />
 <br />
 21 		Glyceraldehyde-3-phosphate Dehydrogenase Enhances Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells. 	<br />
  		</p>

<p>Harada, Naoki; Yasunaga, Ryoko; Higashimura, Yasuki; Yamaji, Ryoichi; Fujimoto, Katsumi; Moss, Joel; Inui, Hiroshi; Nakano, Yoshihisa; ; 2007-06-08<br />
  	  	</p>

<p>Androgen receptor (AR) functions as a transcriptional factor for genes involved in proliferation and differentiation of normal and cancerous prostate cells. Coactivators that bind to AR are required for maximal androgen action.<br />
  		</p>

<p>The Journal of biological chemistry<br />
  		</p>

<p>PubMed Database<br />
 <br />
 22 		HPLC for stress-free screening of potential prostate cancer marker catechol estrogens in urine using a diamond-electrode electrochemical and a fluorescence detector. 	<br />
  		</p>

<p>Katayama, Masatoki Takamatsu, Kiyoshi Kaneko, Satoru Miyaji, Keisuke Ishikawa, Hiromichi Matsuda, Yoshifumi ; 2007-08-03<br />
  	  	</p>

<p>Improvement of the sensitivity and specificity of a simultaneous stress-free screening method for catechol estrogens as a potential prostate cancer marker ... the sensitivity and specificity of the prostatic<br />
  		</p>

<p>PubMed Database<br />
 <br />
 23 		Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. 	<br />
  		</p>

<p>Tomlins, Scott A; Laxman, Bharathi; Dhanasekaran, Saravana M; Helgeson, Beth E; Cao, Xuhong; Morris, David S; Menon, Anjana; Jing, Xiaojun; Cao, Qi; Han, Bo; Yu, Jindan; Wang, Lei; Montie, James E; Rubin, Mark A; Pienta, Kenneth J; Roulston, Diane; Shah,...; 2007-08-03<br />
  	  	</p>

<p>Recently, we identified recurrent gene fusions involving the 5' untranslated region of the androgen-regulated gene TMPRSS2 and the ETS (E26 transformation-specific) family genes ERG, ETV1 or ETV4 in most prostate cancers.<br />
  		</p>

<p>Nature<br />
  		</p>

<p>PubMed Database<br />
 <br />
 24 		cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. 	<br />
  		</p>

<p>Wu, D; Zhau, H E; Huang, W-C; Iqbal, S; Habib, F K; Sartor, O; Cvitanovic, L; Marshall, F F; Xu, Z; Chung, L W K; ; 2007-02-22<br />
  	  	</p>

<p>Aberrant expression of vascular endothelial growth factor (VEGF) is associated with human prostate cancer (PCa) metastasis and poor clinical outcome. We found that both phosphorylation of cyclic AMP-responsive element-binding protein (CREB) ...<br />
  		</p>

<p>Oncogene<br />
  		</p>

<p>PubMed Database<br />
 <br />
 25 		A Refined Comorbidity Measurement Algorithm for Claims-Based Studies of Breast, Prostate, Colorectal, and Lung Cancer Patients. 	<br />
  		</p>

<p>Klabunde, Carrie N Legler, Julie M Warren, Joan L Baldwin, Laura-Mae Schrag, Deborah ; 2007-05-29<br />
  	  	</p>

<p>PURPOSE: We evaluated (i) how combining comorbid conditions identified from Medicare inpatient or physician ... linked database, from which four cohorts of cancer patients were derived: breast (n = 26,377), prostate (n = 53,503), colorectal (n<br />
  		</p>

<p>PubMed Database<br />
 <br />
 26 		Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells. 	<br />
  		</p>

<p>Lee, Dong I; Sumbilla, Carlota; Lee, Myounghee; Natesavelalar, Chidambaram; Klein, Michael G; Ross, Douglas D; Inesi, Giuseppe; Hussain, Arif; ; 2007-05-04<br />
  	  	</p>

<p>Cells with increasing resistance to the sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPase (SERCA) inhibitor thapsigargin (TG), ranging from 60-fold (PC3/TG(10) cells) ... Thus, novel TG-specific resistance mechanisms are recruited by these cancer cells.<br />
  		</p>

<p>Archives of biochemistry and biophysics<br />
  		</p>

<p>PubMed Database<br />
 <br />
 27 		Targeting Human {gamma}{delta} T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer. 	<br />
  		</p>

<p>Dieli, Francesco; Vermijlen, David; Fulfaro, Fabio; Caccamo, Nadia; Meraviglia, Serena; Cicero, Giuseppe; Roberts, Andrew; Buccheri, Simona; D'Asaro, Matilde; Gebbia, Nicola; Salerno, Alfredo; Eberl, Matthias; Hayday, Adrian C; ; 2007-08-03<br />
  	  	</p>

<p>The increasing evidence that gammadelta T cells have potent antitumor activity suggests ... trial in metastatic hormone-refractory prostate cancer to examine the feasibility and consequences of using the gammadelta T-cell agonist zoledronate,<br />
  		</p>

<p>Cancer research<br />
  		</p>

<p>PubMed Database<br />
 <br />
 28 		Guggulsterone-Induced Apoptosis in Human Prostate Cancer Cells Is Caused by Reactive Oxygen Intermediate Dependent Activation of c-Jun NH2-Terminal Kinase. 	<br />
  		</p>

<p>Singh, Shivendra V; Choi, Sunga; Zeng, Yan; Hahm, Eun-Ryeong; Xiao, Dong; ; 2007-08-03<br />
  	  	</p>

<p>Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, causes apoptosis in cancer cells but ... We now show that guggulsterone-induced cell death in human prostate cancer cells is caused by reactive oxygen intermediate (ROI)-dependent activation of c-Jun NH(2)-terminal kinase (JNK).<br />
  		</p>

<p>Cancer research<br />
  		</p>

<p>PubMed Database<br />
 <br />
 29 		Tendon abnormalities mimicking metastatic disease in patients with prostate cancer. 	<br />
  		</p>

<p>Kerimoglu, Ulku; Kaya, Diana; Ergen, Fatma Bilge; ; 2007-08-02<br />
  	  	</p>

<p>We present plain x-ray examination, bone scintigraphy, computed tomography, and magnetic resonance imaging of 2 patients diagnosed with prostate cancer who complained of hip pain. Bone scintigraphy was suggestive for metastases.<br />
  		</p>

<p>Clinical nuclear medicine<br />
  		</p>

<p>PubMed Database<br />
 <br />
 30 		Blood biomarkers for prostate cancer detection and prognosis. 	<br />
  		</p>

<p>Shariat, Shahrokh F Karam, Jose A Roehrborn, Claus G ; 2007-07-31<br />
  	  	</p>

<p>Prostate cancer is the most noncutaneous malignancy diagnosed in men in the USA. The discovery of prostate-specific antigen (PSA) revolutionized prostate cancer diagnosis and management in the 1990s.<br />
  		</p>

<p>PubMed Database<br />
 <br />
 31 		Prostate-specific antigen kinetics after failure of primary prostate cancer therapy: a valuable prognostic factor. 	<br />
  		</p>

<p>Pickles, Tom; ; 2007-07-31<br />
  	  	</p>

<p>Evaluation of: Freedland SJ, Humphreys EB, Mangold LA et al.: Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause ...<br />
  		</p>

<p>Future oncology (London, England)<br />
  		</p>

<p>PubMed Database<br />
 <br />
 32 		Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure. 	<br />
  		</p>

<p>Jackson, Crystal L; Dreaden, Tina M; Theobald, Lisa K; Tran, Nhien M; Beal, Tiffany L; Eid, Manal; Gao, Mu Yun; Shirley, Robert B; Stoffel, Mark T; Kumar, M Vijay; Mohnen, Debra; ; 2007-05-22<br />
  	  	</p>

<p>Treatment options for androgen-independent prostate cancer cells are limited. Therefore, it is critical to identify agents that induce death of both androgen-responsive and androgen-insensitive cells.<br />
  		</p>

<p>Glycobiology<br />
  		</p>

<p>PubMed Database<br />
 <br />
 33 		Stem cells in prostate cancer initiation and progression. 	<br />
  		</p>

<p>Lawson, Devon A; Witte, Owen N; ; 2007-08-03<br />
  	  	</p>

<p>... paradigm shift in our understanding of cancer as a disease of stem cells. This Review focuses on the application of these concepts to investigation of the role of stem cells in prostate cancer initiation and progression.<br />
  		</p>

<p>The Journal of clinical investigation<br />
  		</p>

<p>PubMed Database<br />
 <br />
 34 		Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients. 	<br />
  		</p>

<p>Cai, Tommaso; Bartoletti, Riccardo; ; 2007-08-01<br />
  	  	</p>

<p>Journal of clinical oncology : official journal of the American Society of Clinical Oncology<br />
  		</p>

<p>PubMed Database<br />
 <br />
 35 		Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. 	<br />
  		</p>

<p>Lecouvet, Frédéric E; Geukens, Daphné; Stainier, Annabelle; Jamar, François; Jamart, Jacques; d'Othée, Bertrand Janne; Therasse, Patrick; Berg, Bruno Vande; Tombal, Bertrand; ; 2007-08-01<br />
  	  	</p>

<p>PURPOSE To evaluate the diagnostic performance, costs, and impact on therapy of one-step magnetic resonance imaging (MRI) of the axial skeleton (MRIas) for detecting bone metastases in patients with high-risk prostate cancer<br />
  		</p>

<p>Journal of clinical oncology : official journal of the American Society of Clinical Oncology<br />
  		</p>

<p>PubMed Database<br />
 <br />
 36 		Subcutaneous midazolam as a cause of extrapyramidal side effects in a patient with prostate cancer. 	<br />
  		</p>

<p>Brown, Duncan J F; McArthur, Dorothy; Moulsdale, Helen; ; 2007-07-03<br />
  	  	</p>

<p>Journal of pain and symptom management<br />
  		</p>

<p>PubMed Database<br />
 <br />
 37 		Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. 	<br />
  		</p>

<p>Gudmundsson, Julius; Sulem, Patrick; Steinthorsdottir, Valgerdur; Bergthorsson, Jon T; Thorleifsson, Gudmar; Manolescu, Andrei; Rafnar, Thorunn; Gudbjartsson, Daniel; Agnarsson, Bjarni A; Baker, Adam; Sigurdsson, Asgeir; Benediktsdottir, Kristrun R; Jako...; 2007-07-03<br />
  	  	</p>

<p>We performed a genome-wide association scan to search for sequence variants conferring risk of prostate cancer using 1,501 Icelandic men with prostate cancer and 11,290 controls. Follow-up studies involving three additional ...<br />
  		</p>

<p>Nature genetics<br />
  		</p>

<p>PubMed Database<br />
 <br />
 38 		Prostate cancer screening an individual decision. 	<br />
  		</p>

<p>Holcomb, Susan Simmons; ; 2007-08-02<br />
  	  	</p>

<p>The Nurse practitioner<br />
  		</p>

<p>PubMed Database<br />
 <br />
 39 		[Imaging procedures to diagnose prostate cancer.] 	<br />
  		</p>

<p>Seitz, M Scher, B Scherr, M Tilki, D Schlenker, B Gratzke, C Schipf, A Stanislaus, P Müller-Lisse, U Reich, O Stief, C ; 2007-08-01<br />
  	  	</p>

<p>Prostate cancer is one of the most frequent malignant diseases in men. ... progress achieved in imaging procedures, prostate biopsy is the gold standard for diagnosing prostate cancer.<br />
  		</p>

<p>PubMed Database<br />
 <br />
 40 		Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. 	<br />
  		</p>

<p>Pickles, Tom Ruether, J Dean Weir, Lorna Carlson, Linda Jakulj, Fabijana the SCRN Communication Team† ; 2007-05-30<br />
  	  	</p>

<p>OBJECTIVES To review the psychosocial needs of men undergoing active surveillance (AS, the monitoring of early prostate cancer, with curative intervention only if the disease significantly progresses) for prostate cancer, ...<br />
  		</p>

<p>PubMed Database<br />
 <br />
 41 		Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. 	<br />
  		</p>

<p>Tam, L; McGlynn, L M; Traynor, P; Mukherjee, R; Bartlett, J M S; Edwards, J; ; 2007-06-28<br />
  	  	</p>

<p>The main cause of prostate cancer-related mortality is the development of hormone-refractory disease. ... IL-6 are raised in hormone-refractory prostate cancer patients and evidence from cell line studies suggests that the ...<br />
  		</p>

<p>British journal of cancer<br />
  		</p>

<p>PubMed Database<br />
 <br />
 42 		Association between FAS polymorphism and prostate cancer development. 	<br />
  		</p>

<p>Lima, L Morais, A Lobo, F Calais-da-Silva, F M Calais-da-Silva, F E Medeiros, R ; 2007-08-02<br />
  	  	</p>

<p>The role of FAS polymorphisms in prostate cancer has not been studied. ... -670 genotypes in DNA from 904 men: 657 prostate ... inhibition caused by the soluble form.Prostate Cancer and Prostatic Diseases<br />
  		</p>

<p>PubMed Database<br />
 <br />
 43 		Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. 	<br />
  		</p>

<p>Halabi, Susan Ou, San-San Vogelzang, Nicholas J Small, Eric J ; 2007-08-01<br />
  	  	</p>

<p>BACKGROUND.: Obesity has a variety of adverse health outcomes, but to the authors' knowledge, the effect of obesity on outcome in patients with advanced prostate cancer is not known. ... with metastatic, castration-recurrent prostate ...<br />
  		</p>

<p>PubMed Database<br />
 <br />
 44 		A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. 	<br />
  		</p>

<p>Gross, Mitchell Higano, Celestia Pantuck, Allan Castellanos, Olga Green, Erica Nguyen, Koo Agus, David B ; 2007-07-31<br />
  	  	</p>

<p>ABSTRACT: BACKGROUND: Docetaxel is the standard first-line agent for the treatment of androgen-independent prostate cancer (AIPC). ... toxicity of cytotoxic chemotherapy for prostate cancer.<br />
  		</p>

<p>PubMed Database<br />
 <br />
 45 		Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. 	<br />
  		</p>

<p>Saigal, Christopher S Gore, John L Krupski, Tracey L Hanley, Janet Schonlau, Matthias Litwin, Mark S And the Urologic Diseases in America Project ; 2007-07-28<br />
  	  	</p>

<p>BACKGROUND.: The use of androgen deprivation therapy (ADT) in the treatment of men with prostate cancer has risen sharply. ... common reason for death among men with prostate cancer who do not die of the disease itself, data ...<br />
  		</p>

<p>PubMed Database<br />
 <br />
 46 		The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy. 	<br />
  		</p>

<p>Vickers, Andrew J Ulmert, David Serio, Angel M Björk, Thomas Scardino, Peter T Eastham, James A Berglund, Göran Lilja, Hans ; 2007-07-28<br />
  	  	</p>

<p>Both benign and malignant prostate diseases elevate total prostate-specific antigen (tPSA), and the incidence of ... fPSA, tPSA and hK2 were measured in archived plasma collected during 1974-1986 in 501 men subsequently diagnosed with prostate cancer up to 1999 and in 1,292 matched controls.<br />
  		</p>

<p>PubMed Database<br />
 <br />
 47 		The androgen receptor and prostate cancer: A role for sexual selection and sexual conflict? 	<br />
  		</p>

<p>Summers, Kyle Crespi, Bernard ; 2007-07-28<br />
  	  	</p>

<p>We propose and evaluate the hypothesis that the CAG repeat region of the androgen receptor represents a locus ... However, short repeats are also associated with increased risk of prostate cancer, and with more aggressive forms of the disease.<br />
  		</p>

<p>PubMed Database<br />
 <br />
 48 		IS OBESITY A RISK FACTOR FOR PROSTATE CANCER? 	<br />
  		</p>

<p>Goldstraw, Miles A Besrani, Dler Amoroso, Peter Kirby, Roger S ; 2007-07-31<br />
  	  	</p>

<p>PubMed Database<br />
 <br />
 49 		Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. 	<br />
  		</p>

<p>Ismail, Mohamed Ahmed, Shwan Kastner, Christof Davies, John ; 2007-07-31<br />
  	  	</p>

<p>OBJECTIVE To report the short- to intermediate-term experience of using salvage targeted cryoablation of the prostate (TCAP) for the recurrence of localized prostate cancer after radiotherapy.<br />
  		</p>

<p>PubMed Database<br />
 <br />
 50 		The role of intermittent androgen deprivation in prostate cancer. 	<br />
  		</p>

<p>Boccon-Gibod, Laurent Hammerer, Peter Madersbacher, Stephan Mottet, Nicolas Prayer-Galetti, Tommaso Tunn, Ulf ; 2007-07-31<br />
  	  	</p>

<p>PubMed Database<br />
 <br />
 51 		Targeting uPA/uPAR in prostate cancer. 	<br />
  		</p>

<p>Li, Y Cozzi, P J ; 2007-07-31<br />
  	  	</p>

<p>Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite significant advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to secondary disease ...<br />
  		</p>

<p>PubMed Database<br />
 <br />
 52 		PSA Nadir Is a Significant Predictor of Treatment Failure after High-Intensity Focussed Ultrasound (HIFU) Treatment of Localised Prostate Cancer. 	<br />
  		</p>

<p>Ganzer, Roman Rogenhofer, Sebastian Walter, Bernhard Lunz, Jens-Claudio Schostak, Martin Wieland, Wolf F Blana, Andreas ; 2007-07-31<br />
  	  	</p>

<p>OBJECTIVES: To assess if prostate-specific antigen (PSA) nadir is an independent predictor of treatment failure and disease-free ... (Ablatherm((R)), EDAP, Lyon, France) for localised prostate cancer without previous hormonal therapy were evaluated retrospectively.<br />
  		</p>

<p>PubMed Database<br />
 <br />
 53 		Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. 	<br />
  		</p>

<p>Doak, Shareen H; Jenkins, Spencer A; Hurle, Rhidian A; Varma, Murali; Hawizy, Azad; Kynaston, Howard G; Parry, James M; ; 2007-07-28<br />
  	  	</p>

<p>Abnormal expression of bone morphogenic proteins (BMP) has been reported in prostate cancer as compared to benign prostatic tissue. ... this possibility in patients with early prostate cancer.<br />
  		</p>

<p>Cancer genetics and cytogenetics<br />
  		</p>

<p>PubMed Database</p>]]>
    </content>
</entry>
<entry>
    <title> Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice.</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/prostate_cancer_treatment/immunotherapy/preventive_and_therapeutic_vac.html" />
    <link rel="service.edit" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141/entry_id=36565" title=" Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice." />
    <id>tag:thalasar.com,2007:/Prostate//141.36565</id>
    
    <published>2007-02-27T15:13:56Z</published>
    <updated>2007-02-27T15:13:59Z</updated>
    
    <summary> Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Related Articles Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic...</summary>
    <author>
        <name></name>
        
    </author>
            <category term="Immunotherapy" />
    
    <content type="html" xml:lang="en" xml:base="http://thalasar.com/Prostate/">
        <![CDATA[ <br><a target="_blank" href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=16738849&dopt=Abstract     '>Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice.     </a><br>  <table border="0" width="100%"><tr><td align="left"><a target="_blank" href="http://dx.doi.org/10.1007/s00262-006-0184-0"><img src="http://www.ncbi.nlm.nih.gov/entrez/query/egifs/http:--production.springer.de-OnlineResources-Logos-springerlink.gif" border="0"/></a> </td><td align="right"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Display&amp;dopt=PubMed_PubMed&amp;from_uid=16738849">Related Articles</a></td></tr></table>         <p><b>Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice.</b></p>         <p>Cancer Immunol Immunother. 2007 Feb;56(2):217-26</p>         <p>Authors:  Machlenkin A, Azriel-Rosenfeld R, Volovitz I, Vadai E, Lev A, Paz A, Goldberger O, Reiter Y, Tzehoval E, Benhar I, Eisenbach L</p>         <p>Conventional treatment of recurrent and metastasized prostate cancer (CaP) remains inadequate; this fact mandates development of alternative therapeutic modalities, such as specific active or passive immunotherapy. Previously, we reported the identification of a novel highly immunogenic HLA-A*0201-restricted Prostatic Acid Phosphatase-derived peptide (PAP-3) by a two-step in vivo screening in an HLA-transgenic (HHD) mouse system. In the present study we aimed at elucidating the efficiency of PAP-3-based vaccine upon active antitumor immunization. To this end we established preventive and therapeutic carcinoma models in HHD mice. The 3LL murine Lewis lung carcinoma clone D122 transduced to express HLA-A*0201 and PAP served as a platform for these models. The HLA-A*0201-PAP-3 complex specific recombinant single chain scFV-PAP-3 antibodies were generated and used to confirm an endogenous PAP processing resulting in PAP-3 presentation by HLA-A*0201. PAP-3 based vaccines significantly decreased tumor incidence in a preventive immunization setting. Therapeutic vaccination of HHD mice with PAP-3 led to rejection of early established tumors and to increase of mouse survival. These results strongly support a therapeutic relevance of the identified CTL epitope upon active antitumor immunization. The newly established carcinoma model presented herein might be a useful tool for cancer vaccine design and optimization.</p>         <p>PMID: 16738849 [PubMed - indexed for MEDLINE]</p>          <br>]]>
        
    </content>
</entry>
<entry>
    <title> prostate cancer chemotherapy; +455 new citations</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/prostate_cancer_treatment/chemotherapy/prostate_cancer_chemotherapy_4.html" />
    <link rel="service.edit" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141/entry_id=36564" title=" prostate cancer chemotherapy; +455 new citations" />
    <id>tag:thalasar.com,2007:/Prostate//141.36564</id>
    
    <published>2007-02-27T15:13:41Z</published>
    <updated>2007-02-27T15:13:45Z</updated>
    
    <summary> prostate cancer chemotherapy; +455 new citations 455 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: prostate cancer chemotherapy These PubMed results were generated on 2007/02/27PubMed, a service...</summary>
    <author>
        <name></name>
        
    </author>
            <category term="Chemotherapy" />
    
    <content type="html" xml:lang="en" xml:base="http://thalasar.com/Prostate/">
        <![CDATA[ <br><a target="_blank" href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&db=PubMed&term=(((prostate cancer chemotherapy) AND "2006/09/27 20.02"[MHDA]:"2007/02/27 10.13"[MHDA])) NOT (( ((prostate cancer chemotherapy[TIAB])) AND "0001"[EDAT]:"2006/09/27 20.02"[EDAT]))   '>prostate cancer chemotherapy; +455 new citations   </a><br> <p>455 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: </p> <p align="center"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=%28%28%28prostate+cancer+chemotherapy%29+AND+%222006%2F09%2F27+20%2E02%22%5BMHDA%5D%3A%222007%2F02%2F27+10%2E13%22%5BMHDA%5D%29%29+NOT+%28%28+%28%28prostate+cancer+chemotherapy%5BTIAB%5D%29%29+AND+%220001%22%5BEDAT%5D%3A%222006%2F09%2F27+20%2E02%22%5BEDAT%5D%29%29"><b>prostate cancer chemotherapy</b></a></p> <p>These PubMed results were generated on 2007/02/27</p><p>PubMed, a service of the National Library of Medicine, includes over 15 million  citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals.  PubMed includes links to many sites providing full text articles and other related resources.</p>    <br>]]>
        
    </content>
</entry>
<entry>
    <title> (((prostate cancer treatment) AND &quot;2005/11/13 17.56&quot;[MHDA]:&quot;2115/11/20 14.01&quot;[MHDA])) NOT (( (((prostate cancer[TIAB] AND treatment[TIAB]))) AND &quot;0001&quot;[EDAT]:&quot;2005/11/13 17.56&quot;[EDAT])); +1986 new citations</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/prostate_cancer_treatment/prostate_cancer_treatment_and.html" />
    <link rel="service.edit" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141/entry_id=36563" title=" (((prostate cancer treatment) AND &quot;2005/11/13 17.56&quot;[MHDA]:&quot;2115/11/20 14.01&quot;[MHDA])) NOT (( (((prostate cancer[TIAB] AND treatment[TIAB]))) AND &quot;0001&quot;[EDAT]:&quot;2005/11/13 17.56&quot;[EDAT])); +1986 new citations" />
    <id>tag:thalasar.com,2007:/Prostate//141.36563</id>
    
    <published>2007-02-27T15:13:30Z</published>
    <updated>2007-02-27T15:13:33Z</updated>
    
    <summary> (((prostate cancer treatment) AND &quot;2005/11/13 17.56&quot;[MHDA]:&quot;2115/11/20 14.01&quot;[MHDA])) NOT (( (((prostate cancer[TIAB] AND treatment[TIAB]))) AND &quot;0001&quot;[EDAT]:&quot;2005/11/13 17.56&quot;[EDAT])); +1986 new citations 1986 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search...</summary>
    <author>
        <name></name>
        
    </author>
            <category term="Prostate Cancer Treatment" />
    
    <content type="html" xml:lang="en" xml:base="http://thalasar.com/Prostate/">
        <![CDATA[ <br><a target="_blank" href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&db=PubMed&term=( ((((prostate cancer treatment) AND "2005/11/13 17.56"[MHDA]:"2115/11/20 14.01"[MHDA])) NOT (( (((prostate cancer[TIAB] AND treatment[TIAB]))) AND "0001"[EDAT]:"2005/11/13 17.56"[EDAT]))) AND "2006/08/21 18.52"[MHDA]:"2007/02/27 10.13"[MHDA])   '>(((prostate cancer treatment) AND "2005/11/13 17.56"[MHDA]:"2115/11/20 14.01"[MHDA])) NOT (( (((prostate cancer[TIAB] AND treatment[TIAB]))) AND "0001"[EDAT]:"2005/11/13 17.56"[EDAT])); +1986 new citations   </a><br> <p>1986 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: </p> <p align="center"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=%28+%28%28%28%28prostate+cancer+treatment%29+AND+%222005%2F11%2F13+17%2E56%22%5BMHDA%5D%3A%222115%2F11%2F20+14%2E01%22%5BMHDA%5D%29%29+NOT+%28%28+%28%28%28prostate+cancer%5BTIAB%5D+AND+treatment%5BTIAB%5D%29%29%29+AND+%220001%22%5BEDAT%5D%3A%222005%2F11%2F13+17%2E56%22%5BEDAT%5D%29%29%29+AND+%222006%2F08%2F21+18%2E52%22%5BMHDA%5D%3A%222007%2F02%2F27+10%2E13%22%5BMHDA%5D%29"><b>(((prostate cancer treatment) AND "2005/11/13 17.56"[MHDA]:"2115/11/20 14.01"[MHDA])) NOT (( (((prostate cancer[TIAB] AND treatment[TIAB]))) AND "0001"[EDAT]:"2005/11/13 17.56"[EDAT]))</b></a></p> <p>These PubMed results were generated on 2007/02/27</p><p>PubMed, a service of the National Library of Medicine, includes over 15 million  citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals.  PubMed includes links to many sites providing full text articles and other related resources.</p>    <br>]]>
        
    </content>
</entry>
<entry>
    <title>Claiming Blog in Technorati</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/claiming_blog_in_technorati.html" />
    <link rel="service.edit" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141/entry_id=36178" title="Claiming Blog in Technorati" />
    <id>tag:thalasar.com,2006:/Prostate//141.36178</id>
    
    <published>2006-09-28T01:10:01Z</published>
    <updated>2006-09-28T01:10:23Z</updated>
    
    <summary>Technorati Profile...</summary>
    <author>
        <name></name>
        
    </author>
    
    <content type="html" xml:lang="en" xml:base="http://thalasar.com/Prostate/">
        <![CDATA[<p><a href="http://www.technorati.com/claim/4qj4yh7e5v" rel="me">Technorati Profile</a></p>]]>
        
    </content>
</entry>
<entry>
    <title> The Second International Meeting on Allogeneic Transplantation in Solid Tumors.</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/prostate_cancer_treatment/immunotherapy/_the_second_international_meet.html" />
    <link rel="service.edit" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141/entry_id=36176" title=" The Second International Meeting on Allogeneic Transplantation in Solid Tumors." />
    <id>tag:thalasar.com,2006:/Prostate//141.36176</id>
    
    <published>2006-09-28T01:01:21Z</published>
    <updated>2006-09-28T01:01:25Z</updated>
    
    <summary> The Second International Meeting on Allogeneic Transplantation in Solid Tumors. Related Articles The Second International Meeting on Allogeneic Transplantation in Solid Tumors. Bone Marrow Transplant. 2006 Sep 4; Authors: Bregni M, Ueno NT, Childs R In October 2005, the...</summary>
    <author>
        <name></name>
        
    </author>
            <category term="Immunotherapy" />
    
    <content type="html" xml:lang="en" xml:base="http://thalasar.com/Prostate/">
        <![CDATA[ <br><a target="_blank" href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=16953213&dopt=Abstract     '>The Second International Meeting on Allogeneic Transplantation in Solid Tumors.     </a><br>  <table border="0" width="100%"><tr><td align="left"><a target="_blank" href="http://dx.doi.org/10.1038/sj.bmt.1705479"><img src="http://www.ncbi.nlm.nih.gov/entrez/query/egifs/http:--www.nature.com-images-lo_npg.gif" border="0"/></a> </td><td align="right"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Display&amp;dopt=PubMed_PubMed&amp;from_uid=16953213">Related Articles</a></td></tr></table>         <p><b>The Second International Meeting on Allogeneic Transplantation in Solid Tumors.</b></p>         <p>Bone Marrow Transplant. 2006 Sep 4;</p>         <p>Authors:  Bregni M, Ueno NT, Childs R</p>         <p>In October 2005, the second international meeting on allogeneic transplantation in solid tumors was convened in Stresa (Italy). The aim of this second meeting was to share clinical experiences of allografting in solid tumors, to discuss preclinical data on the mechanisms of graft-versus-tumor (GVT) effect, and to review methods for more efficacious transplant approaches. On the first day, the most recent results in cancer immunotherapy were reviewed; head-to head comparisons of clinical results achieved by standard therapy and by allografting in renal, breast, and ovarian cancer were presented. On the second day, GVT mechanisms and preclinical models were examined; anecdotal reports of a GVT effect in sarcoma, pancreatic cancer, prostate cancer, colorectal cancer and lung cancer were presented; new strategies for optimizing transplant outcome were discussed, including patient selection, tumor debulking, auto-allo approaches, selective T-cell depletion, targeting with monoclonal antibodies, use of killer cell immunoglobulin-like receptor-ligand mismatched natural killer cells. In conclusion, allografting in solid tumors is feasible with limited toxicities and transplant-related mortality; a GVT effect has been documented in many different solid tumors; targeting of the immune response to the tumor by new strategies and identification of the target antigen(s) of the GVT effect are promising areas of research.Bone Marrow Transplantation advance online publication, 4 September 2006; doi:10.1038/sj.bmt.1705479.</p>         <p>PMID: 16953213 [PubMed - as supplied by publisher]</p>          <br>]]>
        
    </content>
</entry>
<entry>
    <title> prostate cancer chemotherapy; +157 new citations</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/prostate_cancer_treatment/chemotherapy/_prostate_cancer_chemotherapy_4.html" />
    <link rel="service.edit" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141/entry_id=36175" title=" prostate cancer chemotherapy; +157 new citations" />
    <id>tag:thalasar.com,2006:/Prostate//141.36175</id>
    
    <published>2006-09-28T01:01:08Z</published>
    <updated>2006-09-28T01:01:12Z</updated>
    
    <summary> prostate cancer chemotherapy; +157 new citations 157 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: prostate cancer chemotherapy These PubMed results were generated on 2006/09/27PubMed, a service...</summary>
    <author>
        <name></name>
        
    </author>
            <category term="Chemotherapy" />
    
    <content type="html" xml:lang="en" xml:base="http://thalasar.com/Prostate/">
        <![CDATA[ <br><a target="_blank" href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&db=PubMed&term=(((prostate cancer chemotherapy) AND "2006/08/21 18.52"[MHDA]:"2006/09/27 20.01"[MHDA])) NOT (( ((prostate cancer chemotherapy[TIAB])) AND "0001"[EDAT]:"2006/08/21 18.52"[EDAT]))   '>prostate cancer chemotherapy; +157 new citations   </a><br> <p>157 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: </p> <p align="center"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=%28%28%28prostate+cancer+chemotherapy%29+AND+%222006%2F08%2F21+18%2E52%22%5BMHDA%5D%3A%222006%2F09%2F27+20%2E01%22%5BMHDA%5D%29%29+NOT+%28%28+%28%28prostate+cancer+chemotherapy%5BTIAB%5D%29%29+AND+%220001%22%5BEDAT%5D%3A%222006%2F08%2F21+18%2E52%22%5BEDAT%5D%29%29"><b>prostate cancer chemotherapy</b></a></p> <p>These PubMed results were generated on 2006/09/27</p><p>PubMed, a service of the National Library of Medicine, includes over 15 million  citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals.  PubMed includes links to many sites providing full text articles and other related resources.</p>    <br>]]>
        
    </content>
</entry>
<entry>
    <title> Health calendar and support groups</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/alternative_prostate_cancer_treatments/_health_calendar_and_support_g.html" />
    <link rel="service.edit" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141/entry_id=35773" title=" Health calendar and support groups" />
    <id>tag:thalasar.com,2006:/Prostate//141.35773</id>
    
    <published>2006-08-21T23:53:38Z</published>
    <updated>2006-08-21T23:53:43Z</updated>
    
    <summary> Health calendar and support groupsOrange County Register - Prevention Program seeks participants for ongoing cholesterol lowering herbal Meetings discussing fertility diagnosis and latest treatments. 6 p.m. last Tuesday Appointments: 714-847-4222, Ext. 231. Prostate cancer support groups. 6:30-8 p.m...</summary>
    <author>
        <name></name>
        
    </author>
            <category term="Alternative Prostate Cancer Treatments" />
    
    <content type="html" xml:lang="en" xml:base="http://thalasar.com/Prostate/">
        <![CDATA[ <br><a target="_blank" href='http://www.ocregister.com/ocregister/healthscience/healthfitness/article_1245513.php'>Health calendar and support groups</a><br>Orange County Register -    Prevention Program seeks participants for ongoing cholesterol lowering herbal   Meetings discussing fertility diagnosis and latest treatments. 6 p.m. last Tuesday   Appointments: 714-847-4222, Ext. 231.     Prostate cancer support groups. 6:30-8 p.m   <br>]]>
        
    </content>
</entry>
<entry>
    <title> Prostate Cancer Screening - Serum levels of phytanic acid are associated with prostate cancer risk.</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/prostate_cancer_screening/_prostate_cancer_screening_ser_1.html" />
    <link rel="service.edit" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141/entry_id=35772" title=" Prostate Cancer Screening - Serum levels of phytanic acid are associated with prostate cancer risk." />
    <id>tag:thalasar.com,2006:/Prostate//141.35772</id>
    
    <published>2006-08-21T23:53:23Z</published>
    <updated>2006-08-21T23:53:30Z</updated>
    
    <summary> Serum levels of phytanic acid are associated with prostate cancer risk. Related Articles Serum levels of phytanic acid are associated with prostate cancer risk. J Urol. 2005 Nov;174(5):1824 Authors: Walsh PC PMID: 16217297 [PubMed - indexed for MEDLINE]...</summary>
    <author>
        <name></name>
        
    </author>
            <category term="Prostate Cancer Screening" />
    
    <content type="html" xml:lang="en" xml:base="http://thalasar.com/Prostate/">
        <![CDATA[ <br><a target="_blank" href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=16217297&dopt=Abstract     '>Serum levels of phytanic acid are associated with prostate cancer risk.     </a><br>  <table border="0" width="100%"><tr><td align="left"/><td align="right"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Display&amp;dopt=PubMed_PubMed&amp;from_uid=16217297">Related Articles</a></td></tr></table>         <p><b>Serum levels of phytanic acid are associated with prostate cancer risk.</b></p>         <p>J Urol. 2005 Nov;174(5):1824</p>         <p>Authors:  Walsh PC</p>         <p></p>         <p>PMID: 16217297 [PubMed - indexed for MEDLINE]</p>          <br>]]>
        
    </content>
</entry>
<entry>
    <title> GU radiation oncologists consensus on bone loss from androgen deprivation.</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/prostate_cancer_prevention/_gu_radiation_oncologists_cons.html" />
    <link rel="service.edit" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141/entry_id=35771" title=" GU radiation oncologists consensus on bone loss from androgen deprivation." />
    <id>tag:thalasar.com,2006:/Prostate//141.35771</id>
    
    <published>2006-08-21T23:53:09Z</published>
    <updated>2006-08-21T23:53:14Z</updated>
    
    <summary> GU radiation oncologists consensus on bone loss from androgen deprivation. Related Articles GU radiation oncologists consensus on bone loss from androgen deprivation. Can J Urol. 2006 Feb;13(1):2962-6 Authors: Duncan GG, Corbett T, Lukka H, Warde P, Pickles T The...</summary>
    <author>
        <name></name>
        
    </author>
            <category term="Prostate Cancer Prevention" />
    
    <content type="html" xml:lang="en" xml:base="http://thalasar.com/Prostate/">
        <![CDATA[ <br><a target="_blank" href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=16515750&dopt=Abstract     '>GU radiation oncologists consensus on bone loss from androgen deprivation.     </a><br>  <table border="0" width="100%"><tr><td align="left"/><td align="right"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Display&amp;dopt=PubMed_PubMed&amp;from_uid=16515750">Related Articles</a></td></tr></table>         <p><b>GU radiation oncologists consensus on bone loss from androgen deprivation.</b></p>         <p>Can J Urol. 2006 Feb;13(1):2962-6</p>         <p>Authors:  Duncan GG, Corbett T, Lukka H, Warde P, Pickles T</p>         <p>The majority of GU radiation oncologists in Canada attended a consensus meeting in November 2004. The topic of osteoporosis in men receiving androgen deprivation therapy (ADT) for prostate cancer was identified as a key theme. A chaired session with keynote speakers and review of the evidence took place followed by open debate. Participants were provided with background information. Osteoporosis was defined as a T-score &lt; or = -2.5, but the importance of risk factors and clinical findings is noted. Dual DEXA is the current standard for assessment of bone density and relates well to fracture risk. The lifetime risk of fracture is 13% for men over the age of 50 years even without the influence of ADT. Lifestyle, dietary and supplementation advice are provided both to prevent and to manage osteoporosis. The role for prophylactic bisphosphonate therapy in men on ADT without osteoporosis has not been established. Follow-up DEXA scans are required to monitor density, risk and response to interventions. Fracture incidence and BMD should be considered in the trial design of studies involving prolonged ADT. Osteoporosis is a treatable condition and the oncologist should employ ADT with this knowledge. A follow-up e-mail survey was carried out regarding the consensus statement. Responses were received from 49 of the 69 attendees (71%), and overall there was an 89% agreement with the consensus statement. This is now adopted as national practice guidelines for radiation oncologists employed prolonged ADT in prostate cancer patients.</p>         <p>PMID: 16515750 [PubMed - indexed for MEDLINE]</p>          <br>]]>
        
    </content>
</entry>
<entry>
    <title> Molecular biology in prostate cancer.</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/prostate_cancer_genetics/_molecular_biology_in_prostate.html" />
    <link rel="service.edit" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141/entry_id=35770" title=" Molecular biology in prostate cancer." />
    <id>tag:thalasar.com,2006:/Prostate//141.35770</id>
    
    <published>2006-08-21T23:52:57Z</published>
    <updated>2006-08-21T23:53:01Z</updated>
    
    <summary> Molecular biology in prostate cancer. Related Articles Molecular biology in prostate cancer. Clin Transl Oncol. 2006 Mar;8(3):148-52 Authors: Cansino Alcaide JR, Mart nez-Pi eiro L Genes involved in cancer generation are usually tumor suppressors and oncogenes. Progressive genetic alterations...</summary>
    <author>
        <name></name>
        
    </author>
            <category term="Prostate Cancer Genetics" />
    
    <content type="html" xml:lang="en" xml:base="http://thalasar.com/Prostate/">
        <![CDATA[ <br><a target="_blank" href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=16648113&dopt=Abstract     '>Molecular biology in prostate cancer.     </a><br>  <table border="0" width="100%"><tr><td align="left"/><td align="right"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Display&amp;dopt=PubMed_PubMed&amp;from_uid=16648113">Related Articles</a></td></tr></table>         <p><b>Molecular biology in prostate cancer.</b></p>         <p>Clin Transl Oncol. 2006 Mar;8(3):148-52</p>         <p>Authors:  Cansino Alcaide JR, Mart  nez-Pi  eiro L</p>         <p>Genes involved in cancer generation are usually tumor suppressors and oncogenes. Progressive genetic alterations in these genes are involved in the mechanisms of tumorigenesis. In prostate cancer, additionally several chromosomal loci that should harbor mutated genes have been proposed. Some genes have been found altered in prostate cancer, such as PTEN, TP53, AR, RNASEL (HPC1), ELAC2 (HPC2), CDKN2A and MSR1 and those can be natural targets for new strategies of treatment. Besides, gene therapy has been suggested to be suitable for prostate cancer treatment. This approach includes ex vivo corrective therapy, suicide, and antisense therapy.</p>         <p>PMID: 16648113 [PubMed - indexed for MEDLINE]</p>          <br>]]>
        
    </content>
</entry>
<entry>
    <title> Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/prostate_cancer_treatment/vaccine_therapy/_sipuleucelt_apc_8015_apc8015.html" />
    <link rel="service.edit" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141/entry_id=35769" title=" Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon." />
    <id>tag:thalasar.com,2006:/Prostate//141.35769</id>
    
    <published>2006-08-21T23:52:44Z</published>
    <updated>2006-08-21T23:52:49Z</updated>
    
    <summary> Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon. Related Articles Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon. Drugs R D. 2006;7(3):197-201 Authors: Sipuleucel-T [APC 8015, Provenge] is an autologous, dendritic cell-based vaccine under development with Dendreon Corporation for the treatment...</summary>
    <author>
        <name></name>
        
    </author>
            <category term="Vaccine therapy" />
    
    <content type="html" xml:lang="en" xml:base="http://thalasar.com/Prostate/">
        <![CDATA[ <br><a target="_blank" href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=16752945&dopt=Abstract     '>Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.     </a><br>  <table border="0" width="100%"><tr><td align="left"/><td align="right"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Display&amp;dopt=PubMed_PubMed&amp;from_uid=16752945">Related Articles</a></td></tr></table>         <p><b>Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.</b></p>         <p>Drugs R D. 2006;7(3):197-201</p>         <p>Authors: </p>         <p>Sipuleucel-T [APC 8015, Provenge] is an autologous, dendritic cell-based vaccine under development with Dendreon Corporation for the treatment of androgen-independent and androgen-dependent prostate cancer. It was generated using the company's active immunotherapy platform to stimulate a patient's own immune system to specifically target and destroy cancer cells, while leaving healthy cells unharmed. This approach could provide patients with a meaningful survival benefit and an improved tolerability profile over existing anticancer therapies. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in approximately 95% of prostate cancers. It is produced by ex vivo exposure of dendritic cell precursors to PA 2024, a recombinant fusion protein composed of the PAP target fused to granulocyte-macrophage colony-stimulating factor (GM-CSF) and incorporated into Dendreon's proprietary Antigen Delivery Cassette. Patients are typically administered three intravenous (IV)-infusions of the vaccine over a 1-month period as a complete course of therapy. It is undergoing late-stage clinical evaluation among patients with early and advanced prostate cancer. In November 2003, Kirin Brewery returned to Dendreon the full rights to Sipuleucel-T for Asia. In exchange, Dendreon licensed patent rights relating to the use of certain HLA-DR antibodies to Kirin for $US20 million. This amended agreement enables Dendreon to complete ongoing discussions for a worldwide marketing and sales partnership for Sipuleucel-T. Similarly, Kirin is able to develop its HLA-DR monoclonal antibodies free of potential infringement claims arising from Dendreon's patent rights to HLA-DR. The licensing agreement relates to patent rights owned by Dendreon relating to monoclonal antibodies against the HLA-DR antigen. In addition, Dendreon retains rights to develop and commercialise its two existing HLA-DR monoclonal antibodies, DN 1921 and DN 1924, as well as other HLA-DR antibodies not being developed by Kirin. Previously, in May 1999, Dendreon and Kirin established a collaboration for the development of dendritic cell-based immunotherapeutics for cancer, including Sipuleucel-T. Under the agreement, Kirin would provide financial support for Dendreon's research on dendritic cells focused on developing immunotherapies for cancers most prevalent in Asia. Dendreon would retain US rights to products arising from the collaboration while Kirin would hold the rights to such immuno-therapeutics in Asia and Oceania. In August 2005, Dendreon signed an agreement to lease a commercial manufacturing facility in Hanover, New Jersey, USA. The company intends to develop the facility to meet anticipated clinical and commercial demands of Sipuleucel-T as well as other active immunotherapy product candidates. Dendreon and Diosynth Biotechnology (Akzo Nobel) have an agreement for the commercial production of the PA 2024 antigen component of Sipuleucel-T. In November 2003, Dendreon announced that Diosynth successfully manufactured PA 2024 on a commercial scale. In October 2001, Dendreon announced that Gambro Healthcare Inc. would provide a network of centres for cell collection to support commercial production and clinical development of various Dendreon vaccines, including Sipuleucel-T. Dendreon has outsourced its cell processing operations in Mountain View, California, USA to Progenitor Cell Therapy under an amended agreement signed in August 2002. This agreement is an expansion of an existing agreement, under which Progenitor provided Dendreon with cell-processing services through its facility in Hackensack, New Jersey, USA. The pivotal, two-stage, phase III trial (D9902 study) has been initiated at clinical sites in the US. The first stage of the trial (D9902A study) is a double-blind, placebo-controlled phase III trial designed to evaluate Sipuleucel-T in men with asymptomatic, metastatic, androgen-independent prostate cancer. The trial was originally designed to be the companion study to a previously completed phase III trial, called D9901. However, the D9902A study with 98 patients recruited was halted in December 2002, when analysis of the D9901 study revealed no statistically significant benefit in time to disease progression in the overall group, although a benefit was seen in a subgroup of patients with Gleason scores of &lt; or =7. In April 2002, the US FDA requested clarification regarding cellular composition of Sipuleucel-T and the suspension of additional patient enrollment for the D9902 study; the request was related solely to manufacturing issues without patient safety being an issue. Trial enrollment resumed in October 2002 following FDA authorisation. Dendreon amended the protocol for the D9902 study and is only recruiting patients with asymptomatic, metastatic, androgen-independent prostate cancer, regardless of their Gleason Score (D9902B study). The ongoing pivotal phase III trial underwent a Special Protocol Assessment (SPA) with the FDA in August 2003 and is enrolling approximately 500 patients. The primary endpoint is overall survival with time to objective disease progression being a secondary endpoint. Final 3-year survival analysis of the D9902A study has been completed and presented. Previously, Dendreon completed an earlier phase III trial (D9901 study) that assessed Sipuleucel-T among 127 patients with late-stage, metastatic, hormone-independent prostate cancer in the US. All subjects had undergone surgical resection of the prostate, but had rising levels of PSA. Final 3-year survival data have been reported. Dendreon also conducted a phase II trial, known as D9905, that investigated Sipuleucel-T monotherapy among patients with early-stage prostate cancer. Study findings have been reported. In September 2003, the FDA designated Sipuleucel-T as a fast-track development programme for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer. Subsequently, the FDA granted fast-track status to the vaccine in November 2005. Dendreon announced in September 1999 that a phase I trial of Sipuleucel-T in patients with prostate cancer had commenced in Japan. This study was being conducted at a dendritic cell processing centre that was formed as part of Dendreon's collaboration with Kirin. In addition, the US NCI is conducting a phase II trial (P-16) of Sipuleucel-T in combination with bevacizumab among patients with hormone-dependent prostate cancer. Trial results have been announced. In April 2001, Dendreon was awarded a US patent (No. 6,210,662) covering the composition of Sipuleucel-T. Dendreon acquired an exclusive worldwide licence to dendritic cell therapy for cancers and other diseases from the Immune Response Corporation; Immune Response originally received the exclusive patent rights to the technology from the University of Brussels in Belgium.</p>         <p>PMID: 16752945 [PubMed - indexed for MEDLINE]</p>          <br>]]>
        
    </content>
</entry>
<entry>
    <title> Distorted rectal tissue on prostate needle biopsy: a mimicker of prostate cancer.</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/prostate_cancer_treatment/surgery/_distorted_rectal_tissue_on_pr.html" />
    <link rel="service.edit" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141/entry_id=35768" title=" Distorted rectal tissue on prostate needle biopsy: a mimicker of prostate cancer." />
    <id>tag:thalasar.com,2006:/Prostate//141.35768</id>
    
    <published>2006-08-21T23:52:31Z</published>
    <updated>2006-08-21T23:52:37Z</updated>
    
    <summary> Distorted rectal tissue on prostate needle biopsy: a mimicker of prostate cancer. Related Articles Distorted rectal tissue on prostate needle biopsy: a mimicker of prostate cancer. Am J Surg Pathol. 2006 Jul;30(7):866-70 Authors: Schowinsky JT, Epstein JI Rectal tissue...</summary>
    <author>
        <name></name>
        
    </author>
            <category term="Surgery" />
    
    <content type="html" xml:lang="en" xml:base="http://thalasar.com/Prostate/">
        <![CDATA[ <br><a target="_blank" href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=16819329&dopt=Abstract     '>Distorted rectal tissue on prostate needle biopsy: a mimicker of prostate cancer.     </a><br>  <table border="0" width="100%"><tr><td align="left"><a target="_blank" href="http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00000478-200607000-00011"><img src="http://www.ncbi.nlm.nih.gov/entrez/query/egifs/http:--www.lwwonline.com-pt-pt-core-template-journal-lwwgateway-images-pmlogo.gif" border="0"/></a> </td><td align="right"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Display&amp;dopt=PubMed_PubMed&amp;from_uid=16819329">Related Articles</a></td></tr></table>         <p><b>Distorted rectal tissue on prostate needle biopsy: a mimicker of prostate cancer.</b></p>         <p>Am J Surg Pathol. 2006 Jul;30(7):866-70</p>         <p>Authors:  Schowinsky JT, Epstein JI</p>         <p>Rectal tissue is often seen in needle biopsies of the prostate gland. On rare occasion distorted rectal glands can mimic prostatic adenocarcinoma, an issue not previously addressed in the peer-reviewed literature. We evaluated 16 prostate needle biopsies received in consultation where the submitting pathologist questioned whether a focus of rectal tissue was prostate cancer. In addition to the distorted architecture, features mimicking prostate cancer included: (1) blue-tinged intraluminal mucinous secretions in 10 cases (63%), (2) prominent nucleoli in 6 cases (37%), (3) mitotic activity in 6 cases (37%), (4) extracellular mucin in 5 cases (31%), and (5) adenomatous changes of the rectal tissue in 1 case (6%). Immunohistochemical results further mimicked prostate cancer with negative stains for the basal cell markers high-molecular weight cytokeratin (n=6) and p63 (n=4), and positive stains for racemase in 4 of 5 biopsies. Diagnostic clues to recognizing that these foci were distorted rectal fragments were the presence of (1) lamina propria in 12 cases (75%), (2) rectal tissue located on a detached fragment of tissue in 10 biopsies (63%), (3) associated inflammation in 10 cases (63%), (4) goblet cells in 7 cases (44%), and (5) muscularis propria in 6 cases (37%). In 2 cases, there was negative staining for prostate specific antigen (PSA) and in 1 case negative staining for cytokeratin 7 and positivity for cytokeratin 20. Rectal glands are associated with many of the classical features of prostate cancer, and immunohistochemistry may be misleading. Recognition of these features mimicking prostate cancer and awareness of other findings that are diagnostic of rectal tissue on biopsy can prevent a misdiagnosis of atypical prostate glands or prostate cancer.</p>         <p>PMID: 16819329 [PubMed - indexed for MEDLINE]</p>          <br>]]>
        
    </content>
</entry>
<entry>
    <title> prostate cancer Radiation therapy; +40 new citations</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/prostate_cancer_treatment/radiation_therapy/_prostate_cancer_radiation_the_9.html" />
    <link rel="service.edit" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141/entry_id=35767" title=" prostate cancer Radiation therapy; +40 new citations" />
    <id>tag:thalasar.com,2006:/Prostate//141.35767</id>
    
    <published>2006-08-21T23:52:17Z</published>
    <updated>2006-08-21T23:52:23Z</updated>
    
    <summary> prostate cancer Radiation therapy; +40 new citations 40 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: prostate cancer Radiation therapy These PubMed results were generated on 2006/08/21PubMed,...</summary>
    <author>
        <name></name>
        
    </author>
            <category term="Radiation therapy" />
    
    <content type="html" xml:lang="en" xml:base="http://thalasar.com/Prostate/">
        <![CDATA[ <br><a target="_blank" href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&db=PubMed&term=(((prostate cancer Radiation therapy) AND "2006/08/09 14.44"[MHDA]:"2006/08/21 18.52"[MHDA])) NOT (( ((prostate cancer Radiation therapy[TIAB])) AND "0001"[EDAT]:"2006/08/09 14.44"[EDAT]))   '>prostate cancer Radiation therapy; +40 new citations   </a><br> <p>40 new PubMed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: </p> <p align="center"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=%28%28%28prostate+cancer+Radiation+therapy%29+AND+%222006%2F08%2F09+14%2E44%22%5BMHDA%5D%3A%222006%2F08%2F21+18%2E52%22%5BMHDA%5D%29%29+NOT+%28%28+%28%28prostate+cancer+Radiation+therapy%5BTIAB%5D%29%29+AND+%220001%22%5BEDAT%5D%3A%222006%2F08%2F09+14%2E44%22%5BEDAT%5D%29%29"><b>prostate cancer Radiation therapy</b></a></p> <p>These PubMed results were generated on 2006/08/21</p><p>PubMed, a service of the National Library of Medicine, includes over 15 million  citations for biomedical articles back to the 1950's. These citations are from MEDLINE and additional life science journals.  PubMed includes links to many sites providing full text articles and other related resources.</p>    <br>]]>
        
    </content>
</entry>
<entry>
    <title> Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.</title>
    <link rel="alternate" type="text/html" href="http://thalasar.com/Prostate/prostate_cancer_treatment/immunotherapy/_combination_immunotherapy_wit.html" />
    <link rel="service.edit" type="application/atom+xml" href="http://thalasar.com/mt/mt-atom.cgi/weblog/blog_id=141/entry_id=35766" title=" Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy." />
    <id>tag:thalasar.com,2006:/Prostate//141.35766</id>
    
    <published>2006-08-21T23:52:05Z</published>
    <updated>2006-08-21T23:52:10Z</updated>
    
    <summary> Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Related Articles Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in...</summary>
    <author>
        <name></name>
        
    </author>
            <category term="Immunotherapy" />
    
    <content type="html" xml:lang="en" xml:base="http://thalasar.com/Prostate/">
        <![CDATA[ <br><a target="_blank" href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?tmpl=NoSidebarfile&db=PubMed&cmd=Retrieve&list_uids=16736512&dopt=Abstract     '>Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.     </a><br>  <table border="0" width="100%"><tr><td align="left"><a target="_blank" href="http://dx.doi.org/10.1002/cncr.21956"><img src="http://www.ncbi.nlm.nih.gov/entrez/query/egifs/http:--www3.interscience.wiley.com-images-wiley_interscience_134x30.gif" border="0"/></a> </td><td align="right"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Display&amp;dopt=PubMed_PubMed&amp;from_uid=16736512">Related Articles</a></td></tr></table>         <p><b>Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.</b></p>         <p>Cancer. 2006 Jul 1;107(1):67-74</p>         <p>Authors:  Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ</p>         <p>BACKGROUND: APC8015 (sipuleucel-T) is a cellular prostate cancer vaccine containing autologous antigen-presenting cells (APC) loaded with PA2024, a recombinant prostatic acid phosphatase/granulocyte-macrophage-colony-stimulating factor fusion protein, as the immunogen. Bevacizumab is a recombinant antibody against vascular endothelial growth factor, a proangiogenic protein with inhibitory effects on APC. A clinical trial was conducted to determine the prostate-specific antigen (PSA) and immunomodulatory effects of this combination immunotherapy. METHODS: Patients with androgen-dependent prostate cancer who had received prior definitive therapy with nonmetastatic, recurrent disease as manifested by a rising PSA of between 0.4 ng/mL and 6.0 ng/mL were enrolled. APC8015 was given intravenously(i.v.) on Weeks 0, 2, and 4. Bevacizumab was given at a dose of 10 mg/kg i.v. on Weeks 0, 2, 4, and every 2 weeks thereafter until toxicity or disease progression. PSA changes were recorded and the PSA doubling time (PSADT) was calculated. Immune response versus PA2024 was measured at baseline and after treatment by T-cell proliferation and interferon-gamma enzyme-linked immunospot (ELISPOT) assays. RESULTS: Twenty-two patients were treated. One patient achieved a &gt; or =50% decrease in PSA. Nine patients exhibited some decrease in PSA from baseline, ranging from 6% to 72%, with the PSA of 3 patients decreasing at least 25%. The median pretreatment PSADT for the 20 evaluable patients was 6.9 months and the median posttreatment PSADT was 12.7 months (P = .01). All patients demonstrated induction of an immune response against PA2024. CONCLUSIONS: The combination of APC8015 and bevacizumab induces an immune response and modulates PSA in patients with biochemically recurrent prostate cancer.</p>         <p>PMID: 16736512 [PubMed - indexed for MEDLINE]</p>          <br>]]>
        
    </content>
</entry>

</feed> 

